Market revenue in 2023 | USD 98.4 million |
Market revenue in 2030 | USD 144.0 million |
Growth rate | 5.6% (CAGR from 2023 to 2030) |
Largest segment | Inhaled |
Fastest growing segment | Other Allergens |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhaled, Drug, Other Allergens, Food |
Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Inhaled was the largest segment with a revenue share of 49.39% in 2023. Horizon Databook has segmented the Denmark allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
The market in Denmark is projected to grow at an exponential rate due to presence of a wellestablished healthcare infrastructure, high disease burden, and growing demand for noninvasive diagnostic tests. Increasing urbanization and industrialization along with sedentary lifestyle are some of the common reasons for increasing incidence of allergies in the country.
Key players are undertaking various strategic initiatives such as mergers & acquisitions and launching new products to expand their presence in the country. Some of the key players in the country are Siemens Healthcare GmbH, GSK, and Sun Pharmaceutical Industries Ltd.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account